Germie van den Dobbelsteen

Dr. Germie van den Dobbelsteen


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
JPJan T. Poolman
Jan T. Poolman
VTVictor Torres
Victor Torres
DMDominique Missiakas
Dominique Missiakas
SWSuzanne P. M. Welten
Suzanne P. M. Welten
JFJeffrey Fernandez
Jeffrey Fernandez
GDGermie van den Dobbelsteen
Germie van den Dobbelsteen
Staphylococcus aureus is a major cause of bacterial infection-related deaths. Increasing antimicrobial resistance highlights the urgent need for effective preventative strategies. Antibody-mediated opsonophagocytosis, the key mechanism for protection against S. aureus, is disabled by critical virulence factors such as Staphylococcal protein A (SpA) and leukocidin AB (LukAB). In our study, we combined genetically detoxified vaccine candidates SpA* and LukAB RARPR-33 with a TH1 adjuvant aiming to restore host antibody functionality. To evaluate these vaccine candidates, we developed both surgical site infection (SSI) and superficial wound infection (SWI) models in minipigs. Our results showed a significant reduction in bacterial load and systemic dissemination in the SSI model, while skin infection severity was markedly decreased after intradermal immunization in the SWI model. This study introduces a novel S. aureus vaccine strategy by targeting immune evasion factors SpA and LukAB, utilizing potent TH1 adjuvants, and employing minipig challenge models.

15 April 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
BJBrian D Johnston
Brian D Johnston
CCConnie Clabots
Connie Clabots
TBTricia Bender
Tricia Bender
SPStephen B. Porter
Stephen B. Porter
GDGermie van den Dobbelsteen
Germie van den Dobbelsteen
James JohnsonJames Johnson
James Johnson
An exceptional gut-colonizing ability may underlie the dramatic epidemiological success of the multidrug-resistant H30R subclone of Escherichia coli sequence type 131 (O25b:K+:H4). In order to inform the development of colonization-preventing measures, we studied systemic immune correlates of H30R intestinal colonization. Human volunteers’ fecal samples were screened for H30R by selective culture and PCR. Subjects were assessed by enzyme immunoassay for serum levels of anti-O25 IgG (representing H30R) and anti-O6 IgG (representing non-H30 E. coli generally), initially and for up to 14 months. Whole blood was tested for the antigen-stimulated release of IFNγ, TNFα, IL-4, IL-10, and IL-17 after incubation with E. coli strains JJ1886 (H30R; O25b:K+:H4) or CFT073 (non-H30; O6:K2:H1). Three main findings were obtained. First, H30R-colonized subjects had significantly higher anti-O25 IgG levels than controls, but similar anti-O6 IgG levels, suggesting an IgG response to H30R colonization. Second, anti-O25 and anti-O6 IgG levels were stable over time. Third, H30R-colonized subjects exhibited a lower TNFα and IL-10 release than controls in response to strain JJ1886 (H30R) relative to strain CFT073 (non-H30R), consistent with TNFα hypo-responsiveness to H30R possibly predisposing to H30R colonization. Thus, H30R-colonized hosts exhibit a sustained serum anti-O25 IgG response and an underlying deficit in TNFα responsiveness to H30R that could potentially be addressed for colonization prevention.

31 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
EWEveline Weerdenburg
Eveline Weerdenburg
SKSusan King
Susan King
JLJoyce Lübbers
Joyce Lübbers
EHElise Hovingh
Elise Hovingh
TDTodd Davies
Todd Davies
JPJan Poolman
Jan Poolman
Extraintestinal pathogenic Escherichia coli (ExPEC) is a major cause of infections of the urinary tract, the bloodstream, and other non-intestinal sites in humans. ExPEC often resists the bactericidal action of human immune defenses including complement, antimicrobial peptides, antibodies, and cell-mediated killing. This review provides an overview of the main host defense strategies, and the mechanisms and molecules ExPEC engages to resist these human immune responses. Surface-exposed polysaccharides, outer membrane proteins, cytotoxins, and proteases are all part of the bacterial arsenal of defenses that can neutralize many of the host’s immune defenses. These factors work in concert to enable ExPEC to survive and thrive in extraintestinal environments of the human body.

6 September 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
MHMiwa Haranaka
Miwa Haranaka
AMAtsushi Momose
Atsushi Momose
YNYoshikazu Nakayama
Yoshikazu Nakayama
YSYuki Saito
Yuki Saito
BSBart Spiessens
Bart Spiessens
MSMichal Sarnecki
Michal Sarnecki
This phase 1 study (NCT04306302) evaluated the safety, reactogenicity, and immunogenicity of ExPEC10V (VAC52416) in healthy Japanese adults. The randomized, double-blind, single-center study included 28-day screening, vaccination (Day 1), 30-day safety and immunogenicity follow-up and 181-day serious adverse events (SAEs) follow-up. Participants (60-85 years) were enrolled in dose-ascending approach and randomized to medium- and high-doses of ExPEC10V (n=8 in each dose group) and placebo (n=8). Incidence of adverse events: solicited AEs (until Day 15), unsolicited AEs (until Day 30), SAEs (until Day 181) and immunogenicity (electrochemiluminescent-based assay [ECL] and multiplex opsonophagocytic assay [MOPA]) were assessed on Day 15 and Day 30. Total of 24 participants were included (median age, 66.5 years; 50.0% female). Incidence of solicited AEs was 81.3% (local) and 18.8% (systemic) for pooled ExPEC10V group (medium-dose ExPEC10V: 75.0% [local], 12.5% [systemic]; high-dose ExPEC10V: 87.5% [local], 25.0% [systemic]). One SAE, not vaccine-related, was reported in high-dose ExPEC10V group after Day 30, which was resolved during study. The ECL demonstrated increase in binding antibody titers, which was maintained from Day 15 to Day 30. For all serotypes, the geometric mean fold increases from baseline on Day 15 ranged from 2.51-10.60 and 1.97-5.23 for medium- and high-dose groups, respectively. The MOPA demonstrated increase in functional antibody responses for all serotypes (except O8) at Day 15 which was maintained from Day 15 to Day 30. ExPEC10V medium- and high-doses were well tolerated with an acceptable safety profile without any significant safety issues in healthy Japanese participants.

18 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JLJoyce Lübbers
Joyce Lübbers
KOKaila Orlandini
Kaila Orlandini
EPEmily Podob
Emily Podob
JFJeffrey Fernandez
Jeffrey Fernandez
JWJolaine M Wilson
Jolaine M Wilson
KBKirsten L. Bair
Kirsten L. Bair
Introduction: Urinary tract infections caused by uropathogenic E. coli (UPEC) affect millions of individuals worldwide. Existing animal models used to study UTI treatment or vaccine efficacy have limitations and cannot accurately predict efficacy in humans. In this study we aimed to establish and optimize an intraurethral UPEC urinary tract infection (UTI) model in Göttingen minipigs with characterization of the strains recovered from the urine. Methods: Foley balloon catheters were used to challenge minipigs intraurethrally with UPEC strain UTI89. Urine collected after challenge was plated for bacterial enumeration and recovered bacteria was tested for agglutination and whole genome sequencing. Results: Through intraurethral challenge with UTI89, we were able to establish infection for 14 days. Agglutination and whole genome sequencing revealed that 75% of the animals were infected with UTI89 challenge strain, while in 25% of the animals, a different E. coli strain was recovered from urine. Therefore, our results emphasize the need for caution when interpreting bacterial enumeration outcomes from UTI models. Careful verification of strain identity is essential to ensure accurate evaluation of intervention effects with vaccine and antibiotic studies. Discussion: Altogether, we describe a novel minipig UTI model using an intraurethral challenge with UPEC strain UTI89 that can be used to assess vaccines and treatment efficacy; and will serve to bridge the gap between preclinical findings and clinical outcomes in humans.

6 October 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
RSRitu Shastry
Ritu Shastry
WSWenchi Shang
Wenchi Shang
SJSarah Janssen
Sarah Janssen
STSarah Tete
Sarah Tete
EDElizabeth Garcia Dominguez
Elizabeth Garcia Dominguez
BMBrian Morrow
Brian Morrow
Accurate O-serotyping of Escherichia coli remains essential for clinical surveillance, outbreak investigation, and evaluation of vaccines targeting invasive E. coli disease. Traditional agglutination-based serotyping is labor-intensive, low-throughput, and reliant on subjective visual interpretation. We developed a high-throughput (HTP) 96-well agglutination assay incorporating automated OD normalization (BioTek Epoch) and objective agglutination quantification using a CTL ImmunoSpot reader. A data-driven positivity cutoff (Total Intensity of Spots per Well < 11.65) was established via Youden’s index to optimize diagnostic discrimination. Validation was performed in a GCLP-compliant laboratory using clinical isolates representing the nine O-serogroups included in the ExPEC9V vaccine candidate. The assay demonstrated 100% sensitivity across all homologous O-serogroups ( n = 9) and ≥95% specificity across heterologous O-serogroups, including five non-ExPEC9V clinical isolates. Robustness was confirmed for bacterial suspensions with OD 600 values of 0.6–1.2, the range recommended for clinical implementation. Long-term stability of boiled cultures stored at 2–8°C was inconsistent—particularly for O75 antisera—supporting same-day preparation of suspensions. Due to heat-associated interference observed with deep-well plastic blocks, glass 96-well tube systems were validated and adopted for clinical testing, demonstrating 100% specificity across all heterologous O-serogroups. This validated HTP agglutination assay provides a scalable, reproducible, and clinically actionable method for E. coli O-serotyping. By preserving the immunologic specificity of conventional agglutination while enabling automation and objective readouts, the assay is well suited for vaccine efficacy studies, reference laboratory workflows, and clinical microbiology programs requiring accurate phenotypic confirmation of O-antigen expression. IMPORTANCE: Agglutination serotyping of bacterial isolates is labor-intensive, requires specialized laboratories and skilled personnel, and relies on subjective visual interpretation. Nevertheless, it remains essential for determining O-antigen expression, providing information that molecular methods—focused only on detecting serotype-specific genes—cannot. For this reason, agglutination O-serotyping continues to serve as the regulatory accepted gold standard. This study describes the development, optimization, and validation of a high-throughput agglutination O-serotyping assay designed to overcome the constraints of low throughput and operator-dependent variability. The validated assay demonstrated its scientific utility through the characterization of clinical isolates from a Phase 3 trial of a candidate Escherichia coli vaccine. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04899336.